5 years ago

Turbine Raises €5.7 Million in Pre-Series A Funding Led by Accel

  • Turbine, a London and Budapest-based biotechnology company, has closed a €5.7 million (USD 6.85 million) pre-Series A funding round led by Accel, with participation from XTX Ventures, Boston Millenia Partners, Delin Ventures, Atlantic Labs, and o2h Ventures

  • Turbine is developing a simulation-based, scalable drug discovery platform called the Simulated Cell™, which unlocks novel therapies for high unmet oncology needs

  • The technology has been validated in numerous collaborations with pharmaceutical companies, including Bayer

  • The platform offers significant benefits over industry standard screening methods by providing granular insight into the molecular mechanism of target-disease interactions.

    • ProblemHealthcare

      "tackle the highest unmet need in oncology diseases"

      Solution

      "developing a simulation-based, scalable drug discovery platform, the Simulated Cell™, which unlocks novel therapies"

      Covered on